Cardiovascular Systems Stock
Price
Target price
€18.20
€18.20
-
-
-
-
05.08.23 / Tradegate
WKN: A0RF8V / Symbol: CSII / Name: Cardiovascular / Stock / Healthcare Equipment & Supplies / Small Cap /
We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Cardiovascular
sharewise wants to provide you with the best news and tools for Cardiovascular, so we directly link to the best financial data sources.
Financials
News
Heartflow Q2 Earnings Call Highlights
Key Points
- Interested in Heartflow, Inc.? Here are five stocks we like better.
- Strong second-quarter growth: Revenue rose 48% year over year to $64.1 million, while global case volume increased
HLS Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in HLS Therapeutics Inc.? Here are five stocks we like better.
- Q2 revenue rose 3.5% to $14.7 million, while adjusted EBITDA declined to $4.7 million due to NILEMDO launch
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial
Key Points
- Interested in Cardiol Therapeutics Inc.? Here are five stocks we like better.
- Cardiol Therapeutics is advancing CardiolRx into the pivotal Phase III MAVERIC trial for preventing
Boston Scientific Q2 Earnings Call Highlights
Key Points
- Interested in Boston Scientific Corporation? Here are five stocks we like better.
- Strong Q2 results, lower outlook: Boston Scientific posted 7% organic revenue growth and adjusted EPS
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
Key Points
- Interested in BioAge Labs, Inc.? Here are five stocks we like better.
- BioAge Labs said its lead drug BGE-102 is on track for near-term data in two areas: a Phase 2 cardiovascular
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
Johnson & Johnson’s (NYSE: JNJ) price action entered consolidation in early March. While it may continue moving sideways or even pull back further, those moves are unlikely, given a convergence of